EcoDrugPlus

Mucosal Pentraxin-Like

Ensembl ID : ENSGEVG00005015803
Gene Symbol: LOC115639485
2 Cross references
499 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Natriuretic Peptide Receptor 2

Ensembl ID : ENSGEVG00005014506
Gene Symbol: NPR2
3 Cross references
260 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Natriuretic Peptide Receptor 3

Ensembl ID : ENSGEVG00005012546
Gene Symbol: NPR3
1 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neuropeptide Y Receptor Y2

Ensembl ID : ENSGEVG00005008967
Gene Symbol: NPY2R
1 Cross references
248 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neuropeptide Y Receptor Y5

Ensembl ID : ENSGEVG00005007231
Gene Symbol: NPY5R
3 Cross references
137 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neurotensin Receptor 1

Ensembl ID : ENSGEVG00005006730
Gene Symbol: NTSR1
3 Cross references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neurotrophic Receptor Tyrosine Kinase 1

Ensembl ID : ENSGEVG00005012376
Gene Symbol: NTRK1
1 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSGEVG00005018338
Gene Symbol: NTRK2
3 Cross references
286 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSGEVG00005013021
Gene Symbol: NTRK3
3 Cross references
271 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nicastrin

Ensembl ID : ENSGEVG00005005080
Gene Symbol: NCSTN
3 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSGEVG00005001861
Gene Symbol: NAMPT
3 Cross references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nischarin

Ensembl ID : ENSGEVG00005011405
Gene Symbol: NISCH
3 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).